Academic Journals Database
Disseminating quality controlled scientific knowledge

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

ADD TO MY LIST
 
Author(s): Yokouchi Hiroshi | Yamazaki Koichi | Kinoshita Ichiro | Konishi Jun | Asahina Hajime | Sukoh Noriaki | Harada Masao | Akie Kenji | Ogura Shigeaki | Ishida Takashi | Munakata Mitsuru | Dosaka-Akita Hirotoshi | Isobe Hiroshi | Nishimura Masaharu

Journal: BMC Cancer
ISSN 1471-2407

Volume: 7;
Issue: 1;
Start page: 51;
Date: 2007;
Original page

ABSTRACT
Abstract Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been well described. However, few studies have investigated the clinical features of gefitinib-responders. In the present study, we analyzed the response and disease progression of primary and metastatic lesions to gefitinib in responders and the results of gefitinib readministration following temporary cessation of gefitinib upon progression of initial gefitinib treatment and other treatments. Method We retrospectively evaluated the clinical courses of 27 NSCLC patients who received gefitinib and achieved either a complete or partial response. Results The best-response rate and disease-control rate against the initial chemotherapy for the gefitinib-responders were 27.3% and 77.3%, respectively. Favorable efficacy was observed in the primary lesion and metastases to the lung, liver and brain, while there was no obvious effect on bone metastasis. The primary lesion and intrapulmonary metastasis were the sites of major recurrence. Median progression-free survival was 13.8 months, median duration of gefitinib treatment was 17.0 months and median overall survival was 29.2 months. Some of the patients who experienced disease progression after responding to gefitinib were again sensitive to readministration of gefitinib following temporary cessation of gefitinib and other treatments. Conclusion Patients may still be expected to have prolonged survival if they once responded to gefitinib and then underwent various subsequent treatments followed by readministration of gefitinib. These findings might provide valuable information for the management of gefitinib-responders.

Tango Rapperswil
Tango Rapperswil

     Save time & money - Smart Internet Solutions